EBV LMP1 Antikörper (C-Term)
Kurzübersicht für EBV LMP1 Antikörper (C-Term) (ABIN870474)
Target
Reaktivität
Wirt
Klonalität
Konjugat
Applikation
Klon
-
-
Bindungsspezifität
- AA 369-384, C-Term
-
Verwendungszweck
- Anti-EBV/LMP-1
-
Spezifität
- EBV/LMP-1
-
Immunogen
- Peptide derived from the C-terminal region of Epstein-Barr virus (EBV), Latent Membrane Protein-1 (LMP-1). Antibody recognizes the epitope between Ser369 - Tyr384
-
Isotyp
- IgG
-
-
-
-
Applikationshinweise
- Ready to use antibody dilution. Directly use for application
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Liquid
-
Buffer
- 20 mM Tris-HCI, pH 8.0, Stabilizer: 20 mg/mL BSA, Preservative: 0.05 % sodium azide
-
Konservierungsmittel
- Sodium azide
-
Vorsichtsmaßnahmen
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Lagerung
- 4 °C
-
Informationen zur Lagerung
- +4˚C, Do not freeze!
-
-
- EBV LMP1 (Epstein-Barr Virus Latent Membrane Protein 1 (EBV LMP1))
-
Andere Bezeichnung
- EBV/LMP-1
-
Substanzklasse
- Viral Protein
-
Hintergrund
- Expression of EBV - LMP-1 protein induces changes associated with EBV infections and activation of primary B cells. LMP-1 belongs to the oncoproteins of the EBV latent gene product, expressed in the majority of the EBV-related human cancers and infectious mononucleosis.
-
UniProt
- P03230
Target
-